We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

96 hedge funds and large institutions have $172M invested in Rigel Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 41 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $153M → $172M (+$19.7M)

8% less funds holding

Funds holding: 104 → 96 (-8)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

44% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 41

Holders
96
Holders Change
-8
Holders Change %
-7.69%
% of All Funds
2.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
23
Reduced
41
Closed
18
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$2K

Top Buyers

1
BC
Broadfin Capital
New York
+$5.06M
2
DCM
DAFNA Capital Management
California
+$1.51M
3
California Public Employees Retirement System
California Public Employees Retirement System
California
+$1.16M
4
Marshall Wace
Marshall Wace
United Kingdom
+$735K
5
OAM
Oxford Asset Management
United Kingdom
+$376K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$2.2M
2
BFA
BlackRock Fund Advisors
California
-$1.55M
3
TC
TFS Capital
Pennsylvania
-$1.54M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.48M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.04M +$37.5K +1,855 +4%
BACM
27
Blue Arrow Capital Management
New York
$1.02M -$405K -20,000 -31%
Norges Bank
28
Norges Bank
Norway
$960K – – –
HVC
29
Healthcare Value Capital
New Jersey
$908K – – –
TCIM
30
TIAA CREF Investment Management
New York
$827K -$38.5K -1,903 -5%
Marshall Wace
31
Marshall Wace
United Kingdom
$825K +$735K +36,352 New
TI
32
Telemetry Investments
New York
$681K +$607K +30,000 New
Charles Schwab
33
Charles Schwab
California
$671K -$5.58K -276 -0.9%
BIM
34
BlackRock Investment Management
Delaware
$659K -$138K -6,837 -19%
AllianceBernstein
35
AllianceBernstein
Tennessee
$653K -$3.44K -170 -0.6%
Two Sigma Investments
36
Two Sigma Investments
New York
$608K -$29.6K -1,466 -5%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$585K +$57.6K +2,850 +12%
Goldman Sachs
38
Goldman Sachs
New York
$532K +$280K +13,837 +144%
BG
39
BlackRock Group
United Kingdom
$517K -$749K -37,033 -62%
WMSA
40
Weiss Multi-Strategy Advisers
New York
$499K +$142K +7,000 +47%
MOACM
41
Mutual of America Capital Management
New York
$495K -$410K -20,265 -48%
T. Rowe Price Associates
42
T. Rowe Price Associates
Maryland
$493K – – –
RA
43
Royce & Associates
New York
$489K – – –
RFC
44
Russell Frank Company
Washington
$488K +$88.8K +4,390 +26%
Deutsche Bank
45
Deutsche Bank
Germany
$470K -$151K -7,465 -26%
TC
46
TFS Capital
Pennsylvania
$466K -$1.54M -76,343 -79%
AQR Capital Management
47
AQR Capital Management
Connecticut
$452K -$186K -9,208 -32%
BCM
48
Bridgeway Capital Management
Texas
$449K -$192K -9,490 -32%
OAM
49
Oxford Asset Management
United Kingdom
$426K +$376K +18,567 New
NFA
50
Nationwide Fund Advisors
Ohio
$370K +$18.7K +927 +6%
1
2
3 4 5

RIGL Hedge Fund Activity: Q4 2014 in Review

96 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2014, worth a combined $172M — up 13% from $153M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of RIGL and 12 opened new positions — a net loss of 6 holders — while 41 trimmed existing stakes and 23 added.

The largest buyer was Broadfin Capital, adding an estimated $5.06M. The largest seller was Millennium Management, cutting an estimated $2.2M.

  • 96 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2014, down from 104 in Q3 2014.
  • Funds reported $172M of Rigel Pharmaceuticals stock for Q4 2014, up 13% quarter-over-quarter.
  • 12 funds opened new Rigel Pharmaceuticals positions in Q4 2014 and 18 closed out, a net change of -6 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2014 was Broadfin Capital, an estimated $5.06M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2014 was Millennium Management, an estimated $2.2M sold.

Based on aggregated 13F filings for Q4 2014.